Literature DB >> 8478615

Selective immunosuppression by administration of major histocompatibility complex class II-binding peptides. II. Preventive inhibition of primary and secondary in vivo antibody responses.

J C Guéry1, M Neagu, G Rodriguez-Tarduchy, L Adorini.   

Abstract

The self-mouse lysozyme peptide corresponding to residues 46-62 (ML46-62) binds to the major histocompatibility complex (MHC) class II molecules I-A(k) and it selectively inhibits, when coinjected with antigen, priming of I-A(k)-restricted, antigen-specific T cells. We demonstrate that administration of ML46-62 also inhibits in vivo antibody responses induced by I-A(k)-restricted T helper cells. ML46-62 is able to prevent the primary anti-hen egg white lysozyme (HEL) antibody response induced by the entire HEL molecule in B10.A(4R) mice, expressing only I-A(k) molecules, but not in mice of H-2d haplotype. ML46-62 also strongly decreases, in B10.A(4R) mice, the antibody response to ribonuclease A, a protein antigen unrelated to the MHC blocker, indicating that MHC blockade is the mechanism leading to inhibition of antibody response. This is further supported by the concomitant decrease, in vivo, of complex formation between immunodominant HEL peptides and I-A(k) molecules, preventing I-A(k)-restricted T cell induction. Administration of ML46-62 after antigen priming does not affect ongoing antibody responses, as expected from MHC blockade. A single injection of ML46-62 at the time of protein antigen priming precludes not only the primary, but also the secondary antibody response to a subsequent challenge with soluble protein, even when the challenge is performed several months after priming. Coinjection of antigen and MHC antagonist inhibits production of all antibody isotypes equally well, suggesting that MHC class II blockade affects both Th1- and Th2-type T helper cells. Therefore, these results indicate that administration of MHC class II-binding peptides can efficiently and selectively prevent the induction of T cell-dependent primary and secondary in vivo antibody responses by blocking antigen presentation to class II-restricted T helper cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478615      PMCID: PMC2191012          DOI: 10.1084/jem.177.5.1461

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  40 in total

1.  Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule I-Ak.

Authors:  C A Nelson; R W Roof; D W McCourt; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

2.  Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells.

Authors:  H J Burstein; C M Shea; A K Abbas
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

Review 3.  Approaches toward peptide-based immunotherapy of autoimmune diseases.

Authors:  L Adorini; J C Guéry; S Trembleau
Journal:  Springer Semin Immunopathol       Date:  1992

4.  Inhibition of experimental autoimmune encephalomyelitis by a nonimmunogenic non-self peptide that binds to I-Au.

Authors:  A M Gautam; C I Pearson; A A Sinha; D E Smilek; L Steinman; H O McDevitt
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

Review 5.  Activation and functions of CD4+ T-cell subsets.

Authors:  A K Abbas; M E Williams; H J Burstein; T L Chang; P Bossu; A H Lichtman
Journal:  Immunol Rev       Date:  1991-10       Impact factor: 12.988

6.  Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor.

Authors:  M T De Magistris; J Alexander; M Coggeshall; A Altman; F C Gaeta; H M Grey; A Sette
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

7.  Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand.

Authors:  B D Evavold; P M Allen
Journal:  Science       Date:  1991-05-31       Impact factor: 47.728

8.  Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation.

Authors:  J C Guéry; A Sette; J Leighton; A Dragomir; L Adorini
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

9.  Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone.

Authors:  M H Wauben; C J Boog; R van der Zee; I Joosten; A Schlief; W van Eden
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

10.  Selective modification of a private I-A allo-stimulating determinant(s) upon association of antigen with an antigen-presenting cell.

Authors:  K L Rock; B Benacerraf
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

View more
  1 in total

1.  Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant.

Authors:  J C Guéry; F Ria; L Adorini
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.